Abstract
The article presents a clinical case of very late stent thrombosis in a patient with acute myocardial infarction. The possible reasons and management tactics of such patients are analyzed. Clinical risk factors contributing to the development of thrombosis are considered. An algorithm for follow-up and treatment was defined. The presence of a high risk of thrombosis, diabetes, chronic kidney disease, heart failure, etc. is a prerequisite for the appointment of long-term dual antiplatelet therapy. To assess the risk of stent thrombosis, it is necessary to take into account the criteria of thrombotic and ischemic risks in patients, which, accordingly, evaluates the probability of developing a myocardial infarction or sudden coronary death in patients with acute coronary syndrome, which determine more aggressive management tactics for this group of patients.
References
2. Wright JD, Folsom AR, Coresh J, Sharrett AR, Couper D, et al. The ARIC (Atherosclerosis Risk In Communities) Study: JACC Focus Seminar 3/8. J Am Coll Cardiol 2021;77(23):2939-2959.
3. Ishihara T, Okada K, Kida H, Tsujimura T, Iida O, et al. Long-Term Outcomes and Clinical Predictors of Mortality Following Occurrence of Stent Thrombosis. J Am Heart Assoc. 2022;11(7):e023276. doi: 10.1161/JAHA.121.0232765.
4. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39:119-177.
5. Valgimigli M. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur. Heart J. 2018;14, 39(3):213-260.
6. Cohen H, Efthymiou M, Isenberg DA. Journal of Thrombosis and Haemostasis. 2018;16(6):102.
7. Cutlip DE, Nakazawa G, Krucoff MW, Vorpahl M, Mehran R, et al. Autopsy validation study of the academic research consortium stent thrombosis defi nition. JACC Cardiovasc Interv. 2011;4(5):554-9.
8. Nogic J, Nerlekar N, Soon K, Freeman M, Chan J, et al. Diabetes mellitus is independently associated with early stent thrombosis in patients undergoing drug eluting stent implantation: Analysis from the Victorian cardiac outcomes registry. Catheter Cardiovasc Interv. 2022;99(3):554- 562. doi: 10.1002/ccd.2991310.
9. Kimura T. For the RESTART investigators. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART) / T Kimura, T Morimoto, K Kozuma [et al.]. Circulation. 2010;122:52-61.
10. Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124(5):544-54. doi: 10.1161/CIRCULATIONAHA.111.047498